LivaNova (LIVN) Cash from Financing Activities (2015 - 2026)
LivaNova's (LIVN) quarterly Cash from Financing Activities came in at -$94.2 million in Q1 2026, down 2031.76% year-on-year from $4.9 million in Q1 2025, and down 49.87% quarter-over-quarter from -$62.9 million in Q4 2025.
LivaNova (LIVN) Cash from Financing Activities (2015 - 2026) Analysis & Trends
LivaNova has disclosed Cash from Financing Activities across 12 years of filings, most recently posting -$94.2 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$94.2 million, down 2031.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$375.5 million (down 1531.33% YoY), and the FY2025 annual result was -$285.7 million, down 1639.86% from the prior year.
- Cash from Financing Activities came in at -$94.2 million for Q1 2026 at LivaNova, down from -$62.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $214.9 million in Q1 2022 to a low of -$209.0 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is -$4.4 million (2025), against an average of -$3.5 million.
- Across the five-year window, Cash from Financing Activities surged 2680.18% in 2022 and slumped 2031.76% in 2026, its largest moves.
- LivaNova's Cash from Financing Activities stood at -$1.7 million in 2022, then slumped by 202.84% to -$5.0 million in 2023, then surged by 31.37% to -$3.4 million in 2024, then sank by 1725.9% to -$62.9 million in 2025, then plunged by 49.87% to -$94.2 million in 2026.
- The last three Cash from Financing Activities figures came in at -$94.2 million (Q1 2026), -$62.9 million (Q4 2025), and -$9.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | LivaNova | 4.29 Bn | 3.71 Bn | 243.75 Mn | -94.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.25 Mn |
| Mar 31, 2026 | -94.25 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Dec 31, 2023 | -5.02 Mn |